FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2744932479> ?p ?o ?g. }

• W2744932479 abstract "Positron emission tomography (PET) is poised to become a useful imaging modality in staging and evaluating therapeutic responses in patients with metastatic pancreatic cancer (mPC). This analysis from a phase 1/2 study examined the utility of early PET imaging in patients with mPC treated with nab-paclitaxel plus gemcitabine. Tumors were measured by [18F]2-fluoro-2-deoxyglucose PET/computed tomography (CT) in patients who received nab-paclitaxel 100 (n = 13), 125 (n = 38), or 150 (n = 1) mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Lesion metabolic activity was evaluated at baseline and 6 and 12 weeks postbaseline. Fifty-two patients had baseline and ≥1 follow-up PET scan. The median maximum standardized uptake values per pancreatic lesion in the nab-paclitaxel 100 mg/m2 and 125 mg/m2 cohorts were 5.1 and 6.5, respectively. Among patients who had a metabolic response by PET, those who received nab-paclitaxel 125 mg/m2 had a 4-month survival advantage over those who received 100 mg/m2. All patients in the nab-paclitaxel 125 mg/m2 cohort experienced an early complete metabolic response (CMR; 34%) or partial metabolic response (PMR; 66%). In the nab-paclitaxel 125 mg/m2 cohort, investigator-assessed objective response rates were 77% and 44% among patients with a CMR and PMR, respectively, with no correlation between PET and CT response (Spearman r s = 0.22; P = 0.193). Patients in the nab-paclitaxel 125 mg/m2 cohort with a CMR experienced a significantly longer overall survival vs those with a PMR (median, 23.0 vs 11.2 months; P = 0.011), and a significant correlation was found between best percentage change in tumor burden by PET and survival: for each 1% decrease in PET score, the risk of death decreased by 2%. The majority of primary pancreatic tumors and their metastases were PET avid, and PET effectively measured changes in tumor metabolic activity at 6 and 12 weeks. These results support the antitumor activity of nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 for treating mPC and the utility of PET for measuring treatment response. Treatment response by PET analysis may be considered when evaluating investigational agents in mPC. NCT00398086." @default.
• W2744932479 created "2017-08-17" @default.
• W2744932479 creator A5004915418 @default.
• W2744932479 creator A5006718606 @default.
• W2744932479 creator A5018257387 @default.
• W2744932479 creator A5066084910 @default.
• W2744932479 creator A5067787981 @default.
• W2744932479 creator A5080900202 @default.
• W2744932479 creator A5081187187 @default.
• W2744932479 date "2017-08-03" @default.
• W2744932479 modified "2023-10-09" @default.
• W2744932479 title "18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer" @default.
• W2744932479 cites W1773759946 @default.
• W2744932479 cites W1987369295 @default.
• W2744932479 cites W1993954722 @default.
• W2744932479 cites W2042668154 @default.
• W2744932479 cites W2059277071 @default.
• W2744932479 cites W2059812628 @default.
• W2744932479 cites W2095104234 @default.
• W2744932479 cites W2105747169 @default.
• W2744932479 cites W2108549165 @default.
• W2744932479 cites W2114428747 @default.
• W2744932479 cites W2115658806 @default.
• W2744932479 cites W2119814107 @default.
• W2744932479 cites W2130819559 @default.
• W2744932479 cites W2134933569 @default.
• W2744932479 cites W2139248078 @default.
• W2744932479 cites W2148249328 @default.
• W2744932479 cites W2151253787 @default.
• W2744932479 cites W2160791102 @default.
• W2744932479 cites W2165480504 @default.
• W2744932479 cites W2170202192 @default.
• W2744932479 cites W2286422058 @default.
• W2744932479 doi "https://doi.org/10.1186/s40644-017-0125-5" @default.
• W2744932479 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5543580" @default.
• W2744932479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28774338" @default.
• W2744932479 hasPublicationYear "2017" @default.
• W2744932479 type Work @default.
• W2744932479 sameAs 2744932479 @default.
• W2744932479 citedByCount "6" @default.
• W2744932479 countsByYear W27449324792019 @default.
• W2744932479 countsByYear W27449324792020 @default.
• W2744932479 countsByYear W27449324792022 @default.
• W2744932479 crossrefType "journal-article" @default.
• W2744932479 hasAuthorship W2744932479A5004915418 @default.
• W2744932479 hasAuthorship W2744932479A5006718606 @default.
• W2744932479 hasAuthorship W2744932479A5018257387 @default.
• W2744932479 hasAuthorship W2744932479A5066084910 @default.
• W2744932479 hasAuthorship W2744932479A5067787981 @default.
• W2744932479 hasAuthorship W2744932479A5080900202 @default.
• W2744932479 hasAuthorship W2744932479A5081187187 @default.
• W2744932479 hasBestOaLocation W27449324791 @default.
• W2744932479 hasConcept C121608353 @default.
• W2744932479 hasConcept C126322002 @default.
• W2744932479 hasConcept C126838900 @default.
• W2744932479 hasConcept C143998085 @default.
• W2744932479 hasConcept C2775842073 @default.
• W2744932479 hasConcept C2776694085 @default.
• W2744932479 hasConcept C2777292972 @default.
• W2744932479 hasConcept C2779984678 @default.
• W2744932479 hasConcept C2780210213 @default.
• W2744932479 hasConcept C2780258809 @default.
• W2744932479 hasConcept C2989005 @default.
• W2744932479 hasConcept C31760486 @default.
• W2744932479 hasConcept C71924100 @default.
• W2744932479 hasConcept C72563966 @default.
• W2744932479 hasConcept C90924648 @default.
• W2744932479 hasConceptScore W2744932479C121608353 @default.
• W2744932479 hasConceptScore W2744932479C126322002 @default.
• W2744932479 hasConceptScore W2744932479C126838900 @default.
• W2744932479 hasConceptScore W2744932479C143998085 @default.
• W2744932479 hasConceptScore W2744932479C2775842073 @default.
• W2744932479 hasConceptScore W2744932479C2776694085 @default.
• W2744932479 hasConceptScore W2744932479C2777292972 @default.
• W2744932479 hasConceptScore W2744932479C2779984678 @default.
• W2744932479 hasConceptScore W2744932479C2780210213 @default.
• W2744932479 hasConceptScore W2744932479C2780258809 @default.
• W2744932479 hasConceptScore W2744932479C2989005 @default.
• W2744932479 hasConceptScore W2744932479C31760486 @default.
• W2744932479 hasConceptScore W2744932479C71924100 @default.
• W2744932479 hasConceptScore W2744932479C72563966 @default.
• W2744932479 hasConceptScore W2744932479C90924648 @default.
• W2744932479 hasFunder F4320309086 @default.
• W2744932479 hasFunder F4320332898 @default.
• W2744932479 hasIssue "1" @default.
• W2744932479 hasLocation W27449324791 @default.
• W2744932479 hasLocation W27449324792 @default.
• W2744932479 hasLocation W27449324793 @default.
• W2744932479 hasLocation W27449324794 @default.
• W2744932479 hasOpenAccess W2744932479 @default.
• W2744932479 hasPrimaryLocation W27449324791 @default.
• W2744932479 hasRelatedWork W1430115117 @default.
• W2744932479 hasRelatedWork W1975153720 @default.
• W2744932479 hasRelatedWork W2001578098 @default.
• W2744932479 hasRelatedWork W2006547351 @default.
• W2744932479 hasRelatedWork W2024463098 @default.
• W2744932479 hasRelatedWork W2091019843 @default.
• W2744932479 hasRelatedWork W2100029565 @default.
• W2744932479 hasRelatedWork W2111262996 @default.
• W2744932479 hasRelatedWork W2165480504 @default.

• next